April 1, 2013

$PVCT: Regional Licenses v. Global License vs. Endgame

As management continues to work towards regional license deals in China, India and Japan, and sees growing interest from Big Pharma in a global license, it is interesting to note a few things.

Pfizer India is an autonomous organization that can and does enter into transactions in India as it deems appropriate.

Relationships Pfizer has in China are more state-governed, requiring more direct contact between Provectus and local pharmaceutical players there.

Should Provectus enter into a global license with Big Pharma, it neither precludes regional license transactions being contemplated in certain geographies from being done nor does it prevent another Big Pharma from acquiring the company entirely (i.e., the end-game).

No comments:

Post a Comment